 BOSTON and COPENHAGEN, Denmark, June 22, 2021 GLOBE NEWSWIRE -- Galecto, Inc. NASDAQ: GLTO, a publicly listed, clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced preliminary topline results from an investigator-initiated trial examining Galectos inhaled galectin-3 inhibitor GB0139. This trial included 41 hospitalized patients with COVID-19 infection who did not require mechanical ventilation, of which 20 were randomized to the GB0139 arm. 